

## Review

# Progress in Animal Models of Pancreatic Ductal Adenocarcinoma

Kaiwen Kong<sup>1\*</sup>, Meng Guo<sup>2\*</sup>, Yanfang Liu<sup>3✉</sup>, Jianming Zheng<sup>1✉</sup>

1. Pathology Department of Changhai Hospital, Second Military Medical University
2. Institute of Organ Transplantation, Changzheng Hospital, Second Military Medical University, Shanghai, China; National Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University
3. Pathology Department of Changhai Hospital, Second Military Medical University; National Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University

\* Kaiwen Kong and Meng Guo are co-first authors.

✉ Corresponding authors: Yangfang Liu: address: Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R.China, Email: liuyanfang00215@163.com; Tel: +8613918386805; Fax: 021-81873689. Jianming Zheng: address: Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R.China, Email: jmzheng1962@163.com; Tel: +8613386273822; Fax: 021-81873689

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <http://ivyspring.com/terms> for full terms and conditions.

Received: 2019.06.12; Accepted: 2019.11.10; Published: 2020.01.14

## Abstract

As a common gastrointestinal tumor, the incidence of pancreatic cancer has been increasing in recent years. The disease shows multi-gene, multi-step complex evolution from occurrence to dissemination. Furthermore, pancreatic cancer has an insidious onset and an extremely poor prognosis, so it is difficult to obtain clinical specimens at different stages of the disease, and it is, therefore, difficult to observe tumorigenesis and tumor development in patients with pancreatic cancer. At present, no standard protocols stipulate clinical treatment of pancreatic cancer, and the benefit rate of new targeted therapies is low. For this reason, a well-established preclinical model of pancreatic cancer must be established to allow further exploration of the occurrence, development, invasion, and metastasis mechanism of pancreatic cancer, as well as to facilitate research into new therapeutic targets. A large number of animal models of pancreatic cancer are currently available, including a cancer cell line-based xenograft, a patient-derived xenograft, several mouse models (including transgenic mice), and organoid models. These models have their own characteristics, but they still cannot perfectly predict the clinical outcome of the new treatment. In this paper, we present the distinctive features of the currently popular pancreatic cancer models, and discuss their preparation methods, clinical relations, scientific purposes and limitations.

## Introduction

According to NIH statistics, the 5-year survival rate of patients with pancreatic cancer between 2009 and 2015 was only 9.3% in US (<https://seer.cancer.gov/statfacts/html/pancreas.html>). As such, pancreatic cancer is associated with the worst prognosis of any malignancy because it has an insidious onset, high malignancy, special anatomical location, low resection rate, and high recurrence rate, as well as lack typical symptoms. Furthermore, the incidence of the disease increases annually: by 2030, patients with pancreatic cancer are expected to

outnumber those with breast and colorectal cancer in United States, and pancreatic cancer is projected to become the second most common cancer worldwide [1].

Owing to the characteristics of pancreatic cancer, it is difficult for clinicians to obtain samples at different stages and to continuously observe the occurrence and development of pancreatic cancer in individual patients. For this reason, animal models of pancreatic cancer help clinicians to further understand the occurrence, development, invasion,

and metastasis mechanisms of this disease [1], and can even be used to explore new therapeutic means.

In 1941, Wilson discovered that a diet supplemented with 2-acetylaminofluorene induced pancreatic cancer in albino rats [2]. By the late 20<sup>th</sup> century, as the incidence of pancreatic cancer increased, the study of animal models began to develop, with the help from government agencies.

An ideal animal model of pancreatic cancer should have the following characteristics: (1) Abiological development process similar to that of human pancreatic cancer, which is stable and repeatable. Specifically, pancreatic ductal adenocarcinoma (PDAC) mostly develops from precursor lesions, the most common type being ductal intraepithelial neoplasia (PanINs) [3]. Genetic mutations highly correlated with this process have been reported in the literatures [4]. At present, a series of mouse pancreatic cancer models have been constructed using genetic engineering technology. By mutating *Kras*, *Ckn2a*, *Tp53*, *Smad4*, and other genes, researchers can induce ductal intraepithelial neoplasia, and the number of mutant genes is highly correlated to the severity of disease [5]; (2) Malignant phenotype similar to human tumors, such as anti-apoptotic effect, immune escape, invasion and metastasis. A wide variety of pancreatic cancer cell lines are available on the market, with the phenotype and genotype of each representing a specific subtype of pancreatic cancer. Researchers can infer the mechanism of tumorigenesis and development by studying the relationship between the expression of different specific proteins in cell lines and tumor growth, invasion and metastasis; (3) An experimental method that is easy to implement and efficient in terms of labor and time, as well as a short model establishment period. In particular, pancreatic cancer models used in clinical studies of individualized treatment must have a high success rate and be suitable for large-scale preparation to ensure that they provide evidence regarding individualized treatment options for patients with a short survival time.

### Spontaneous tumor animal models

As used herein, the term “spontaneous tumor” refers to a specific tumor induced spontaneously in a laboratory animal using a chemical, viral induction, or experimental genetic techniques. This contrasts with a transplanted tumor. Spontaneous tumors are more similar to human tumors, so results from animal models of such tumors can be more easily extrapolated to humans. However, the occurrence of spontaneous tumors may vary, so it is difficult to obtain a large amount of tumor material in a short

period of time. Moreover, the observation time is long, and the experiment is expensive.

### 1. Chemically induced animal models

**Rat:** Wistar and Lewis rats are injected intraperitoneally with azaserine to induce acinar cell carcinoma of the pancreas, with liver, lung and lymph node metastasis [6, 7]. However, the lesions in this model lack a typical duct-like structure and of ten occur alongside tumors of other organs (mammary, liver, kidney). The chemicals 4-hydroxyaminoquinoline-1-oxide [8], nafenopin [9], clofibrate [10], N-(N-methyl-N-nitrosamide)-L-ornithine [11] and different N-nitro compounds [7] can induce acinar cell lesions without a duct-like structure. Vesselinovitch et al. found that topical benzopyrene can induce adenocarcinoma in rats. They implanted dimethylbenzanthracene crystal powder into the pancreas of Sprague-Dawley rats, and approximately 80% of them developed spindle cell sarcoma and poorly differentiated adenocarcinoma. Other researchers using this method have found ductal cell proliferation, tubular adenocarcinoma, acinic cell carcinoma, fibrosarcoma, and invasive ductal adenocarcinoma.

**Hamster:** Hamsters are one of the best animal models for inducing pancreatic cancer. For instance, some carcinogens that work in hamsters are ineffective in other animals, such as rats, mice, Dutch pigs, and rabbits. N-Nitroso-bis(2-oxopropyl)amine (BOP) has the highest specificity in this regard [12, 13], and it shows a specific affinity for the pancreas, although its mechanism has not yet been confirmed. This N-Nitroso-BOP model shows unique characteristics that are similar to a well-characterized series of morphologic changes that occurs in the human pancreatic duct, and it frequently shows point mutations in codon 12 of the *Kras* gene, concurring with findings in human pancreatic cancer [14, 15]. Meijers found that the early pseudoductular lesions, induced by BOP in the exocrine pancreas of hamsters originate from proliferating ductal/ductular acinar cells rather than proliferating dedifferentiated acinar cells [16]. In addition, the tumors induced in hamsters are most similar to human tumors in terms of morphology, clinical features, and biological manifestations. Not only benign and malignant tumors but also some rare lesions occurred in hamsters. Tumors in hamsters, just as in humans, may show perineural invasion, involvement of the lymph nodes adjacent to the pancreas, weight loss, diarrhea, ascites, and thrombosis. Occasionally, the tumors also involve jaundice, because they mainly occur in the body and tail of the pancreas. Similar to human tumors, serum antigens CA125, 17-1A, TAG-72,

TFGR- $\alpha$ , EGFR, and lectin have been detected in hamster pancreatic tumors, and glucose tolerance has been observed. However, carcinoembryonic antigen, pancreatic cancer embryonal antigen, and  $\alpha$ -fetal protein are low or unexpressed [17]. Animal models like the hamster model of pancreatic cancer can help identify known and emerging human risk factors and implement appropriate interventions.

## 2. Genetically engineered mouse model of pancreatic cancer

Many recent studies have used genetic technology to introduce oncogenes into mouse embryonic or somatic cells through tissue-specific promoters targeting the pancreas and inducing pancreatic cancer. Genetically Engineered Mouse Models (GEMMs) are constructed using transgenic, gene knock-in, and gene knock-out techniques to transfer specific genes into mice via retroviruses. Most currently used GEMMs are developed using *Kras* proto-oncogenes. The transgenic mice that overexpress the mutant *Kras* gene can mimic pancreatic tumorigenesis. They found that physiological levels of *Kras*<sup>G12D</sup> induce ductal lesions that recapitulate the full spectrum of human pancreatic intraepithelial neoplasias (PanINs), putative precursors to invasive pancreatic cancer [18]. As most human pancreatic cancers are ductal adenocarcinomas, researchers preferred the selected promoter to be limited to the ductal epithelial or exocrine cells. Most single genetically modified models cannot reproduce the whole process of pancreatic tumorigenesis, and the progression from the normal epithelium to cancer cells often requires four to five genetic mutations [19]. Additional genetic modifications, such as *P53* and *P16* inactivation, can accelerate tumorigenesis and metastasis. Conditional gene knockout technology allows gene modification to be limited to a certain part or a certain stage of development, so the time and space of the mutant gene can be accurately controlled, enabling more accurate study of gene function. The Cre/loxP recombinase [20] and tet-on systems [21] are the most commonly used conditional gene knockout strategies [22]. GEMMs of pancreatic cancer are similar in nature to the human disease. In particular, their metastasis pattern is the most similar to that of human pancreatic cancer. The model can be used to study early-stage tumor formation, allowing researchers to ascertain tumor pathogenesis and the effects of therapy. However, the model is limited because it is genetically and biologically different from the human tumor, its modeling time is difficult to control, and its cost is high. Furthermore, it is difficult to meet experimental requirements in terms of quantity.

### KIC model (Pdx1-Cre, LSL-Kras<sup>G12D</sup>, Ink4a/Arf<sup>lox/lox</sup>)

The Pdx1 (pancreatic duodenal homeobox-1) gene which expressed in pre-pancreatic endoderm starting at embryonic stage, would express in acinar and other endocrine cells during development, thus Pdx1-Cre could drive gene modification in all pancreatic cell types [23]. Based on Pdx1-Cre mice, several spontaneous pancreatic cancer models were established. Among those models, KIC is the most notable one. The deficiency of cyclin-dependent kinase inhibitor 2A (*Cdkn2a*, *Ink4a*) gene, whose inactivation is associated with melanoma-pancreatic cancer syndrome in human, would not cause the spontaneous pancreatic cancer. But combined with pancreas-specific Cre-mediated activation of a mutant *Kras* allele (*Kras*<sup>G12D</sup>) can result in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers (duodenum, stomach and spleen), resulting in death in all cases by 11 weeks [24].

### KPC model (Pdx1-Cre, LSL-Kras<sup>G12D</sup>, LSL-Trp53<sup>R172H/+</sup>)

Higori's team has targeted concomitant endogenous expression of *Trp53*<sup>R172H</sup> and *Kras*<sup>G12D</sup> to the mouse pancreas, revealing the cooperative development of invasive and widely metastatic carcinoma that recapitulates the human disease [25]. In such model, the spontaneous cancer in pancreas can cause liver and lung metastasis about 2.5 months. Many of the classical features of malignancy in general and of pancreatic cancer in specific can be recapitulated by *Ink4a/Arf* loss in the setting of *Kras* activation.

### KD model (Pdx1-Cre, LSL-Kras<sup>G12D</sup>, Smad4<sup>lox/lox</sup>)

Smad proteins are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor (TGF)- $\beta$  signaling, and its inactivation is common in pancreatic cancer. Some researchers have targeted oncogenic *Kras* expression and conditional *Smad4/Dpc4* deletion to progenitor cells of the murine pancreas [26, 27]. They found that most mouse had IPMN lesions in pancreas with the slow progression of tumor.

### PDAC model by TGFBR2 knockout with *Kras* (Prfla-Cre, LSL-Kras<sup>G12D</sup>, Tgfbr2<sup>lox/lox</sup>)

Pancreas associated transcription factor 1a (*Prfla*) plays a role in determining whether cells allocated to the pancreatic buds continue towards pancreatic organogenesis or revert back to duodenal fates. The protein is thought to be involved in the maintenance of exocrine pancreas-specific gene

expression including elastase 1 and amylase. Mutations in this gene cause cerebellar agenesis and loss of expression is seen in ductal type pancreas cancers [28]. TGFBR2 is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with TGF-beta receptor type-1, and binds TGF-beta. TGF-beta signaling plays an important role in PDAC progression, as indicated by the fact that *Smad4*, which encodes a central signal mediator downstream from TGF-beta, is deleted or mutated in 55% and the type II TGF-beta receptor (*Tgfb2*) gene is altered in a smaller subset of human PDAC. The *Tgfb2* knockout combined with *Kras(G12D)* expression developed well-differentiated PDAC with 100% penetrance and a median survival of 59 days [29]. And the clinical and histopathological manifestations of the combined *Kras(G12D)* expression and *Tgfb2* knockout mice recapitulated human PDAC. Such models indicate that blockade of TGF-beta signaling and activated Ras signaling cooperate to promote PDAC progression and is better for human to study the TGF-beta signaling in the development of PDAC.


#### Tetracycline-induced TetO-Cre (Figure 1):

Cre expression can be activated when rtTA or tTA with transcriptional activation functions bind to tetO. Binding of rtTA or tTA to tetO is regulated by tetracycline or its derivative doxycycline (**Dox**). Specifically, tTA only induces Cre expression when it binds to tetO in the absence of Dox; it does not bind to tetO when Dox is present, so Cre is not expressed in such cases. Concisely, rtTA binds to tetO and induces Cre expression when Dox is present; when Dox is

absent, it does not bind to tetO, and Cre is not expressed. Thus, in tetO-Cre and tissue-specific rtTA (or tTA) **double-transgenic** mice, Cre recombinase can be controlled in space and time by administering or withdrawing Dox. Cre recombinase specifically recognizes the loxp site and cleaves the DNA sequence, causing DNA sequence recombination between the two sites.

#### Establishment of animal models based on cell lines

To understand certain aspects of human pancreatic tumors, such as tumor growth, metastasis, drug efficacy, *etc.*, researchers generally prefer the athymic (nude) mouse, which is a mutant mouse said to be nude because it is hairless due to the presence two copies of the gene "nu" (for nude). Nude mice have no thymus and therefore no T cells, a class of lymphocytes that depend on the thymus to develop. For lack of T cells, nude mice cannot reject tumors or transplants of cells from humans or other animals. The phenotype of the original tumor can be maintained after cancer cells of human origin have been implanted into such models, although some abnormal reactions will occur [30]. However, one recent study used severe combined immunodeficiency mice (SCID), which has the biological characteristics of T cells and B cells combined deficiency, to receive pancreatic cancer cells of human origin. The results showed that differences in immunodeficiency do not affect the occurrence of pancreatic cancer in mice, and that the potential for metastasis is largely determined by the specific cell line [31].



**Figure 1.** Tetracycline-induced TetO-Cre for GEMM. A: Cre mice (TRE-Cre, also called tetO-Cre) controlled by a tetracycline-responsive element (TRE, also called **tetO**). C: Mice expressing a tetracycline-responsive transcriptional activator **rtTA** or **tTA** driven by a tissue-specific promoter.

## 1. Cell line selection

The low diagnostic rate of pancreatic cancer is partly due to a lack of specific molecular changes, so it may be useful for researchers to understand their known cell lines (Table 1). Therefore, before beginning studies on pancreatic tumors, researchers should know what the research direction is. This will allow them to select the appropriate cell line and evaluate its clinical background, growth characteristics in both in vitro and in vivo experiments, and the phenotypic characteristics (adhesion, invasion, metastatic ability [32]), and genotypic changes, which most often occur in the *KRAS*, *SMAD4*, *TP53*, and *P16* genes (Table 2) [33-36].

**Cell genotypes:** Studies have shown that mutations in these four genes are not associated with the degree of differentiation [37] or biological behavior [38] of pancreatic cancer cells. However,

research does indicate that in vivo tumor metastasis related to alterations in the *p53* gene, suggesting that genotype is related to the phenotype in pancreatic cancer cell lines [39, 40].

**Cell metastasis and invasion:** The biological characteristics of tumor metastasis can be understood through cancer cell metastasis experiments. In the Boyden chamber invasion model, cells migrated from one chamber to another through the artificial basement membrane pores at different chemokine concentrations [41]. Other migration experiments include the transwell and scratch assays [42]. Stahle et al. found that PANC-1 cells were five times more active than BxPC-3 cells in the transwell migration experiment [43]. Lin et al. evaluated mobility by measuring the phagocytic trajectory of cell movement on a colloid surface; they found that both HPAF-II and BxPC-3 cells had good mobility [44].

**Table 1.** Human pancreatic cancer cell lines

Cell line	Tissue origin	Metastasis	Doubling time	Differentiation degree	Morphology	Tumor formation rate (subcutaneous)	Ref
AsPC-1	Ascites	Yes	38-40hrs	Poor	Epithelioid		[80]
HPAF-II	Ascites	Yes	42 hrs	Moderate	Epithelioid		[81]
HPAC-1	Primary tumor	-	41hrs	Good	Epithelioid		[82]
MIA PaCa-2	Primary tumor	-	40hrs	Poor	Epithelioid	66%	[83]
PANC-1	Primary tumor	Yes	52hrs	Poor	Epithelioid	86%	[84]
BxPC-3	Primary tumor	No	48-60hrs	Moderate-Poor	Epithelioid	100%	[85]
Capan-2	Primary tumor	No	96hrs	Good			[86]
Capan-1	Liver Metastasis	Yes	-	Good	Epithelioid		[87, 88]
SU.86.86	Liver Metastasis	Yes	77hrs	Moderate-Poor	Epithelioid		[89]
CFPAC-1	Liver Metastasis	Yes	31hrs	Good		100%	[90]
Suit-2	Liver Metastasis	Yes	29-38 hrs				[91, 92]
SW1990	Splenic Metastasis	Yes	64hrs			100%	[93]
Hs766T	Lymphatic Metastasis	Yes	6-7days	-	Epithelioid		[94]
Colo357	Lymphatic Metastasis	Yes	21 hrs	Good			[95]
T3M4	Lymphatic Metastasis	Yes		Moderate			[96]

**Table 2.** Animal-origin pancreatic cancer cell lines

Cell line	Organism	Carcinogen	Differentiation degree	Gene mutation	Ref
PC1	mouse	BOP	Good	K-ras, P53	[97, 98]
WDPaCa	mouse	BOP	Good	P53	[99]
PDPaCa	mouse	BOP	Poor	k-ras	[99]
HPC	mouse	BOP	Poor		[100]
HP1	mouse	BOP			[101]
HaP-T1	mouse	BOP	Good-Moderate		[102]
H2T	mouse	BHP		K-ras, P53	[103, 104]
HPD(1-3)NR	mouse	BHP	Moderate	K-ras, P53	[102, 105]
Pan02	mouse	MCA		K-ras, smad4	[106]
6606PDA	mouse		Good		[107-109]
AR42J	rat				[110, 111]

Note: BHP: N-nitrosobis(2-hydroxypropyl)amine; animal-origin pancreatic cancer cell lines are commonly used in inbred mice of the same origin for allogeneic transplantation. This model is used more frequently in tumor immunology studies and to evaluate single-agent or combination immunotherapy studies.

**Table 3.** Expression of mutant genes in cell lines

Gene	Expression of Cell Line
KRAS	Occurred in almost all of the primary tumors of pancreatic cancer, but the BxPC-3 cell line is WT
SMD4/DPC4	Capan-2, MIA PaCa-2, PANC-1, SU.86.86 without SMD4 gene inactivation
TP53	Its mutation occurs in 50% of pancreatic malignant tumors and is associated with late tumor progression
CDKN2A/P16	Basically all pancreatic cancer cell lines have inactivation of the P16 gene

**Tumorigenicity:** In a study by Schmidt, a pancreatic cancer cell suspension was injected into nude mice. The researchers then observed the volume, quantity, and metastasis of the subsequent tumor to roughly ascertain the tumorigenicity of the cell line. Relatedly, different methods of tumor induction can cause differences in the tumor formation rate and metastatic colonization location. For example, intra-abdominal or intravenous injection, *in situ* implantation, and implantation metastasis show differing outcomes. Subcutaneous injection of tumor cells is the most common experimental method, probably because it is easy to operate. Different cell lines result in tumors of significantly different sizes. In one study, Capan-1, PANC-1, and MIA PaCa-2 cell suspensions were injected into the severe combined immunodeficiency (SCID) mice. After 30 days, a biopsy was taken, revealing the tumor sizes in the following order: MIA PaCa-2 > Capan -1 > PANC-1 [45]. Eibl *et al.* [46] used donor nude mice to grow Capan-2 and MIA PaCa-2 tumors. They then removed the tumor, cut it into a cube of 1×1×1 mm<sup>3</sup>, and implanted it in the pancreatic tail of recipient nude mice. They reported a 100% tumor formation rate and that MIA PaCa-2 tumors grew faster. However, because the tumor was first formed under the skin, this *in situ* tumor implantation model lacks the changes related to the tumor microenvironment and morphology of early-stage tumor. Direct injection of cancer cells into the pancreas can better reflect the tumorigenesis and development of pancreatic cancer. Indeed, several studies have focused on direct injection of different pancreatic cancer cell lines into the pancreas of SCID mice to induce tumor formation [32]. The tumor formation rate were as follows: AsPC-1, 100% (10/10); CFPAC-1, 100% (10/10); HPAF- II, 100% (8/8); Capan-2, 90% (9/10); Hs 766T, 90% (9/10); HPAC, 88% (7/8); PANC-1, 80% (8/10); and BxPC-3, 67% (6/9).

## 2. Establishment of a transplanted tumor model

### 2.1 Orthotopic implantation models

***In situ* tumor formation:** *In situ* pancreatic cancer can be induced using *in situ* injection or pancreatic capsule implantation of tumor cells. In the latter case, tumor cells grow subcutaneously for 4 weeks to form a tumor. The tumors are then excised and cut into pieces of 1~2 mm<sup>3</sup>. In recipient mice, the pancreatic capsule is then opened, and the tumor is implanted into the tail of the pancreas. The tumor formation period is 4 weeks, and the rate is 100%; the injection of tumor cell suspension has a lower tumor formation rate than the transplantation method, and the injection port is likely to cause cell shedding, resulting

in extensive transplantation metastasis. For this reason, the method is rarely used [47]. However, researchers have implanted pancreatic cancer cells into a recently developed thermosensitive biogel. The cells then develop into tumors. The gel is liquid at a low temperature and turns into jelly at body temperature, which prevents cell shedding; the gel can also dissolve any intervention drugs and is an excellent model for studying such drug. In general, *in situ* tumor formation of pancreatic cancer can fully simulate the internal environment of tumorigenesis and development, and it can affect the whole body during the tumor evaluation period. With the *in situ* tumor model, the tumorigenesis time is short and the tumorigenesis rate is high, so the original tumor structure is maintained, as are most biological characteristics of the human tumor, including the growth of primary tumor, local invasion, and subsequent distant visceral metastasis. The model is an indispensable for studying the tumor microenvironment and is important for exploring new surgical approaches, nutritional support, and other ancillary treatments for pancreatic cancer.

### 2.2 Ectopic implantation of pancreatic cancer

The classical simplification of metastasis into an orderly sequence of basic steps—local invasion, intravasation, survival in the circulation, extravasation and colonization—has helped to rationalize the complex set of biological properties that must be acquired for a particular malignancy to progress towards overt metastatic disease. These biological events have been described [48], and many genetic and epigenetic events have been identified that contribute to the metastatic path. In all of the metastatic models, pancreatic cancer cells can survive in the circulation, such as lymphatic or blood vascular channels, then lodge in capillaries at destination and attach to and through endothelium. Finally, tumor cells can proliferate and grow as masses. However, in the implantation tumor models, there are still several models that can simulate the whole process of tumor metastasis, such as injection of cells orthotopically into the pancreas and metastasis to liver or lung, as well as spleen injection and metastasis to liver indirectly.

**Subcutaneous tumor formation:** The most common ectopic site of injection is the subcutis. The primary reason for this is convenience: subcutaneous injections are easy to perform, and tumors are readily visible for monitoring growth. This model involves planting tumor cells or tumor tissue directly under the skin of mice. Nude or other immunodeficient mice are generally used in such experiments to study the biological behavior of tumors and intervention

therapy. The model is easy to operate, inflicts little trauma on the mice, and confers a high tumor formation rate (80%-100%). The implantation sites are usually located in the back, neck, armpits, groin, or other areas with a rich supply of blood and lymphatic vessels. The model uses tumor cells in the logarithmic growth phase. Briefly, the cell suspension density is adjusted to  $1-2 \times 10^7$ /mL using PBS, and the cell suspension is injected into the implantation site at a volume of 0.2 mL. The mice are then fed in cages. The tumor formation rate and size differ depending on the cell line used. Although subcutaneous tumor formation is easy to operate and suitable for large-scale experiments, it is limited to subcutaneous growth, without distant metastasis, or internal organ invasion, and it cannot truly reflect the tumor microenvironment of pancreatic cancer. In this way, the model does not match the real human pancreatic cancer, and it is therefore used to assess the response of tumors to specific drugs, including antibody-based and cellular drugs, but not for mechanism studies.

**Liver metastasis model:** At the time of presentation, patients with pancreatic cancer are usually at an advanced stage, with tumor invasion into adjacent structures or metastasis into the peritoneum via direct extension, as well as into the regional lymph nodes or distant organs, such as the liver and lungs [49]. The most commonly used liver metastasis models involve spleen injection and direct intrahepatic implantation. In such models, the spleen is injected with a pancreatic cancer cell line at the logarithmic phase, and a  $1 \times 10^6$ /mL single-cell suspension is prepared using ice-cold sterile PBS. Experimental animals are then anesthetized and disinfected, and the spleen is exposed at a distance of 0.5 cm left of the ventral midline. Next, 100  $\mu$ L of cell suspension is injected slowly using an insulin syringe. Immediately after injection, tissue glue or an alcohol cotton ball are used to prevent bleeding and transplantation metastasis into the abdominal cavity. This liver metastasis model is mainly used to study the invasive ability of pancreatic cancer; it is not applicable to the study of blood flow dissemination. The intrahepatic implantation model is a supplement to the model. In this model, the tumor cell suspension is directly injected into the liver through the portal vein. Tumor tissue from human or experimental animals can then be cut into a 1-mm<sup>3</sup> tumor mass and directly implanted under capsule of the left lobe using a 16-gauge needle. The above models can complement each other and be used to systematically study various cascade processes in which pancreatic cancer develops from the primary tumor, invades and migrates into the blood vessels, and acclimates the microenvironment of the metastatic tumor, allowing

the secondary tumor to grow.

**Lung metastasis model:** The lung metastasis model is established by injection of tumor cells through the tail vein. After the tumor cells enter the capillary network of the lungs through the systemic circulation, they gather in the microvessels of the lungs, and metastatic tumors 1~2 mm in diameter are formed in the lungs after around 1 month. By labeling tumor cells with fluorescent proteins, tumor colonization and growth can be continuously observed under an *in vivo* imaging system. This method also causes tumor formation in organs other than the lungs, such as the liver, so this method is also used to study the hematogenous metastasis.

**Lymph node metastasis model:** The presence or absence of lymphatic metastasis has a guiding role in the treatment of pancreatic cancer, but no imaging method or technique can satisfactorily track lymph node metastasis [50, 51]. Therefore, to better study this phenomenon, a stable lymph node metastasis model for pancreatic cancer is needed. No cell lines have been reported to confer specific lymph node metastasis, and researchers usually screen for such cell lines by continuous screening and planting *in vivo*. For example, Li et al. used the BxPC-3 cell line to produce a highly lymphatic metastatic pancreatic cancer cell line, dubbed BxPC-3-LN5, through repeated screening. They then injected 100  $\mu$ L of  $1 \times 10^9$ /mL cell suspension into the left hindpaw of BALB/C nude mice and observed swollen lymph nodes in the popliteal fossa of the left knee after about 5 weeks [52].

**Perineuronal invasion model:** Patients with pancreatic cancer often have severe pain due to peripheral nerve invasion, which considerably impacts quality of life. Pancreatic cancer has a high incidence of invasion and metastasis into the nerves and plexuses surrounding the arteries, and this is one of the important factors in local recurrence of pancreatic cancer after excision. Therefore, researchers must further explore perineuronal invasion of pancreatic cancer, with a view to reduce patient suffering and improve clinical treatment. Both human and mouse perineuronal invasion models of pancreatic cancer are used. In the former case, the celiac plexus and superior mesenteric artery nerve are obtained from a donor 6 hours after death by postmortem autopsy. Under aseptic conditions, the nerves are then cut into 1-cm pieces and immediately placed in RPMI-1640 medium containing antibiotics. The isolated tissues are implanted subcutaneously in non-obese diabetic (NOD)/SCID mice. After 4 weeks,  $7 \times 10^6$  pancreatic cancer cells are injected near the plantation site. After 5 to 8 weeks, the tumor volume

is around 1.5 cm<sup>3</sup>. The mouse model also uses NOD/SCID mice: 7 × 10<sup>6</sup> pancreatic cancer cells are injected into the midline of the mouse. In this model, it is better to choose a cell line with a tendency towards perineuronal invasion, such as Capan-1 or Capan-2 [53, 54].

### Patient Derived Tumor Xenografts (PDX)

Xenograft models are either created from injecting patient-derived cell lines into immunocompromised mice or from implanting a fragment of the tumor (PDX) into these animals. In the latter model, researchers implant small tumors from a patient's pancreas into experimental immune-compromised mice, simulating their native growth environment [55, 56]. Tumors cultured using this method can better preserve matrix heterogeneity and retain more human tumor matrix components in the early generations (within 10 generations) [57]. They can also retain the histological characteristics of the original tumor, such as morphology, lymphatic and vascular systems and necrotic areas [58]. Moreover, they retain molecular diversity, with at least the first 10 generations showing microarray-comparative genomic hybridization, microsatellite instability, and higher genetic stability—gene sequencing shows that neither the DNA copy number nor the gene expression profile differs significantly between the early and late generation models [59]. This model can reflect the tumor characteristics in individual patients and is necessary to study individualized treatment. However, the cycle time is long and the model's success rate is low. In addition, the most typical feature of pancreatic cancer is rich stromal cells. With the passage of the tumor, the human stromal cells in the tumor are gradually replaced by the mouse cells, so they still cannot truly reflect the original biological behavior.

### Establishment and application of pancreatic cancer organoid

Cell lines, genetically engineered mouse models and transplanted tumor models all have important clinical significance and scientific research value, but each also has clear shortcomings, especially with regards to individualized treatment. The establishment of xenograft tumors requires effort and time, as well as materials. In addition, *in situ* tumor models based on cell lines never truly reflect the patient's condition. Organoid models are artificially controllable and can reproduce the three-dimensional structure of PDAC; it has attracted increasing attention

because it can overcome the limitations of the traditional model. Organoids can be used to study tumorigenesis and tumor development, including the solid and interstitial components of the tumor, and also as a "test bed" to help determine specific treatment options for patients using *in vitro* testing.

*In vitro* culture of the pancreas can be traced back to 1938, when Carrel and Lindberg used the irrigation method to culture a cat's pancreas *in vitro* for 4 weeks [60]. In the 1980s, researchers began to explore how to culture isolated pancreatic cells in a three-dimensional structure [61]. On the basis of previous experience, Speier *et al.* sliced the pancreas of the mouse and then successfully cultured it for 7 days in agarose [62]; the normal human pancreas and pancreatic tumors can be cultured in the same way for 6 days [63]. In a further improvement of this method, part of the normal pancreas and tumor were placed in a collagen or matrix gel and used for drug sensitivity testing [64]. In addition, PDAC cell lines have been directly cultured in a three-dimensional structure [65], using various physical methods to prevent cell adhesion and form a polarized spheroid structure. Lorenzo Moroni's team were aimed to investigate the interactions between human primary PDAC cells and take polymeric scaffolds with different design and composition to create biomimetic models of PDAC [66]. The cultivation of pancreatic cells in a three-dimensional space has allowed researchers to realize the possibility of organoids, but no uniform definition of organoids has yet been agreed.

Clevers *et al.*, working with Tuveson Laboratories [67], found that cells isolated from PDA or PanIN lesions in mice can be cultured into organoids. They prepared pancreatic ductal organoids from multiple murine primary tumors (mT) and metastases (mM). Orthotopic transplantation of mT organoids initially generated low- and high-grade lesions that resembled mPanINs. Over longer periods of time (1–6 months), transplants developed into invasive primary and metastatic mPDA. Similarly, this kind of tumor model is applicable to human pancreatic cancer cells. They researchers modified the culture conditions to support human normal and malignant pancreatic tissues. These patient-derived organoids (PDO) can be cryopreserved and passaged indefinitely, and they can be genetically transcribed, proteinized, and biochemically analyzed. Therefore, this system is an ideal model for exploring tumor progression at each stage. Melissa Skala *et al.* [68] used a similar method to isolate PDA cells in transgenic mice with the following genotype: *Ptf1a Cre/+; Kras LSL-G12D/+; Tgfb2 fl/fl* mice. These cells were cultured in mixed medium and serum-containing medium to develop



into an organoid. This method can be used to culture tumors that have been removed from human pancreatic cancer.

Senthil Muthuswamy *et al.* [69] established three-dimensional culture conditions to induce differentiation of human pluripotent stem cells into exocrine progenitor cells, forming ductal and acinar structures *in vitro* and *in vivo*; they also identified culture conditions for cloning freshly collected PDAC cells into tumor organoids, which can maintain the differentiation status, histological structure, and phenotypic heterogeneity of the primary tumor, as well as preserve the unique physiological changes seen in the patient, including hypoxia, oxygen consumption, epigenetic marks, and sensitivity difference to histone methyltransferase EZH2 inhibition.

Calvin Kuo *et al.* [70] used an "air-liquid interface" (ALI) method in which embryonic tissue fragments were cultured in type I collagen gels built on a permeable substrate with a medium underneath that allows nutrients to diffuse from the bottom. The top of the medium was exposed to the air so that the cells could obtain a higher level of oxygen than in conventional culture methods, thereby preventing hypoxia. In the ALI culture, a pancreatic tissue from newborn mice formed an organoid surrounded by stromal cells and containing ductal epithelial cells. It could survive for 50 days without exogenous growth factors, but cannot be passaged. Later, the researchers cultured pancreatic organoids from *Kras<sup>LSL-G12D/+</sup>* and *Trp53<sup>fl/fl</sup>* mice.

In most organoid studies in the cancer field, primary carcinoma samples have been generated under adult stem cell (ASC)-organoid conditions. However, CRISPR mutagenesis technology has been applied to pluripotent stem cell (PSC)-based organoids to generate cancer-causing mutations. Organoid cultures allow several parameters to be observed: (1) interpatient variation can be captured and maintained, (2) patient material can be xenotransplanted with high efficiency, (3) the drug response of the corresponding patient can be faithfully reproduced, and (4) drug sensitivities of PDOs can be recapitulated in PDX settings. The organoid model is highly efficient, so a corresponding organoid biobanks can be established on the basis of different tumor types. Indeed, several studies have reported that organoids can be derived from needle biopsies taken from liver cancer [71], pancreatic cancer [72, 73], or human colorectal cancer metastases [74]. In the studies of colorectal cancer, two laboratories separately have established human intestinal cell organoids containing mutant tumor suppressor genes and oncogenes, which can be used

to study the mechanism of tumorigenesis and invasion [75, 76]. In the near future, pancreatic organoids will likely play a key role in the development of precision medical treatment against PDAC, which will have its own unique advantages.

## Discussion

Many studies revealed that pancreas-specific *Kras* mutation can induce spontaneous pancreatic cancer in experimental animals. Meanwhile, the mutations of *Kras* are found in more than 90% of human pancreatic ductal carcinoma specimens [77]. The most frequent mutation is the constitutively active *KRAS<sup>G12D</sup>* allele [78]. Thus the study based on *Kras* mutated models can facilitate researchers to understand the tumorigenesis and development of pancreatic cancer. However, animal models based on single mutation of *Kras* might be insufficient to explore the landscape of pancreatic cancer biological behavior on account of its tumorigenesis and development is an extremely complex and long-term process. Epidemiological data also indicates that smoking, high-calorie diet, chronic pancreatitis, and type 2 diabetes can increase the risk of pancreatic cancer, which prompts that the oncogenesis and progression of pancreatic cancer is a multifactorial process. This process is a result of the interaction of oncogenes, tumor suppressor genes, metabolic environment, immune system, *etc.* However, until now there is no effective and reliable animal models can completely simulate the pathological process of pancreatic cancer. At present, a practical and feasible method is to combine several different models, such as pancreatic cancer model with type 2 diabetes induced by injection of STZ into KIC mice with high-fat diet, pancreatitis-pancreatic cancer model established by bombesin injecting into KIC mice, and KIC mice intervened with smoking, high-fat or high-cholesterol diet. All of these models aim to explore the key biology event of pancreatic cancer. In addition, iDTR-CRE system in the pancreatic cancer model can achieve the depletion of a certain immune cell subsets. By this system we can explore which immune subsets play a pivotal role in maintaining immune surveillance and anti-tumor function in the process of pancreatic cancer. Furthermore with the development of *in vivo* screening CRISPR/Cas9 technology genes' novel function may be identified directly in the pathogenesis of pancreatic cancer, including non-coding RNAs. And new pancreatic cancer related animal model may be established. Now main current view summarizes the occurrence of pancreatic cancer as a consecutive biological event: *Kras* mutation and *Her2* overexpression could cause intraepithelial neoplasia of the pancreas, tumor suppressor genes

*p16*, *p53*, *DPC4* and *BRCA2* may dysfunction in the immunol suppressive microenviroment, eventually leading to pancreatic cancer. Many effective therapies have been developed for pancreatic cancer burden mice, which can control pancreatic cancer in animal models and even eliminate tumors. However, the current clinical challenge is that pancreatic cancer is still difficult for early detection, lack of effective treatment and very poor prognosis. Pancreatic Ductal Adenocarcinoma's five-year survival rate is still less than 10%, the majority of patients already lost surgery opportunity when found. The present dilemma is mainly reflected in two aspects: firstly, no effective biomarkers of pancreatic cancer have been found in the current study. How to use animal models combined with circulating tumor cell monitoring technology, cfDNA sequencing technology, metabolomics and so on to find new tumor markers is the future research should be concerned. Secondly, the study of single gene mutation animal models will inevitably lose sight of one another, and it will be difficult to exert the landscape of tumor. Only by introducing multiple pathogenic factors into animal models and leading multi-target therapy strategies, especially introducing microsurgery intervention, all of these above will be possible to provide practical theoretical basis for the clinical treatment of pancreatic cancer.

It is true that tumor associated microenvironment plays an important role in the development and progression of cancer. Researchers have recognized that every process of tumor is driven by cooperation between cancer cells and their microenviroment, including relevant fibroblasts, immune cells and other specific interstitial cells. Because of the specificity of pancreas, pancreatic cancer microenviroment includes numerous fibroblasts, pancreatic stellate cells, nerve tissue, immune cells and vascular related cells. These different types of cells not only provide survival soil for the proliferation and malignant evolution of cancer cells, but also are important factors for pancreatic cancer to escape immune surveillance and even "counteract" the immune system. How to realize "mimics" or even "humanized" of pancreatic cancer microenvironment in animal models is a key scientific issue worthy of attention. Although it is difficult to humanize the tumor microenvironment in animal models, the maturity of several new technologies makes this assumption possible. For example, the immune system of patients can be individually reconstructed in severe immunodeficient mice such as NCG/NSG through the method that small molecule compound cocktail inducing long-term expansion of hematopoietic stem progenitor cells *in vitro* [79],

which can also help to the explore the individualized mechanism of tumor immune escape in PDX model.

## Conclusion

Because pancreatic cancer shows no specific early clinical manifestations and has high mortality, medical researchers find it difficult to study the biological behavior and internal mechanisms of early pancreatic cancer, and our understanding of the mechanism underlying tumorigenesis is limited. Early diagnosis allows patients to receive timely treatment in the curable phase. Use of experimental animal models is an important method for gaining insight into the etiology, risk factors, prevention, and treatment of this tumor. Although many mouse models can be obtained using transgenic technology, there is still a lack of specificity for clinical research.

Perhaps importantly, 70% of pancreatic cancers are induced by carcinogens, with nitrosamine and polycyclic aromatic hydrocarbons in tobacco being high risk factors for inducing pancreatic cancer. Therefore, to induce tumorigenesis of pancreatic cancer, chemically induced models are more useful. However, the transplantation tumor model has been used to study etiology, diet, modification factors, and some natural products, as well as early diagnosis, prevention and treatment of pancreatic cancer.

In summary, current animal models can mimic the characteristics of most human pancreatic cancers, but no model has become a "gold standard" that meets the needs of all research. By simply focusing on specific needs and combining the characteristics of each model, researchers can better study the overall process of tumorigenesis and development of pancreatic cancer. Ultimately, to reduce PDAC mortality, judgments based on genetic and non-genetic risk factors must be improved. As such, researchers must explore new biomarkers and high-resolution imaging techniques to screen for patients with early-stage, high risk cancer, and must carry out drug interventions to prevent PDAC progression and prolonging survival time. In the past few decades, improvements in animal models have driven advances in these areas, and these models will continue to make significant contributions in the coming years.

## Acknowledgments

This work was supported by the National Natural Science Foundation of China (81772577, 81602526 and 81602497).

## Competing Interests

The authors have declared that no competing interest exists.

## References

- Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. *The New England journal of medicine*. 2014; 371: 1039.
- Wilson RH, Deeds F, Cox AJ. The Toxicity and Carcinogenic Activity of 2-Acetylaminofluorene. *Cancer Research*. 1941; 1: 595-608.
- Hruban RH, Adsay NV, Alboressaavedra J, Compton C, Garrett ES, Goodman SN, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. *American Journal of Surgical Pathology*. 2001; 25: 579-86.
- Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature*. 2016; 531: 47-52.
- Hruban RH, Takaori K, Klimstra DS, Adsay NV, Alboressaavedra J, Biankin AV, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. *American Journal of Surgical Pathology*. 2004; 28: 977.
- Longnecker DS, Memoli V, Pettengill OS. Recent results in animal models of pancreatic carcinoma: histogenesis of tumors. *Yale J Biol Med*. 1992; 65: 457-64; discussion 65-9.
- Rao MS. Animal models of exocrine pancreatic carcinogenesis. *Cancer Metastasis Rev*. 1987; 6: 665-76.
- Hayashi Y, Hasegawa T. Experimental pancreatic tumor in rats after intravenous injection of 4-hydroxyaminoquinoline 1-oxide. *Gan*. 1971; 62: 329-30.
- Reddy JK, Rao MS. Malignant tumors in rats fed nafenopin, a hepatic peroxisome proliferator. *J Natl Cancer Inst*. 1977; 59: 1645-50.
- Reddy JK, Qureshi SA. Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-alpha-p-chlorophenoxyisobutyrate (clofibrate) in rats. *Br J Cancer*. 1979; 40: 476-82.
- Longnecker DS, Curphey TJ, Lilja HS, French JI, Daniel DS. Carcinogenicity in rats of the nitrosourea amino acid N delta-(N-methyl-N-nitrosocarbonyl)-L-ornithine. *J Environ Pathol Toxicol*. 1980; 4: 117-29.
- Gurski T. [Experimental production of tumors of the pancreas]. *Vopr Onkol*. 1959; 5: 341-8.
- Pour P, Wallcave L, Gingell R, Nagel D, Lawson T, Salmasi S, et al. Carcinogenic effect of N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine, a postulated proximate pancreatic carcinogen in Syrian hamsters. *Cancer Res*. 1979; 39: 3828-33.
- Fujii H, Egami H, Chaney W, Pour P, Pelling J. Pancreatic ductal adenocarcinomas induced in Syrian hamsters by N-nitrosobis(2-oxopropyl)amine contain a c-Ki-ras oncogene with a point-mutated codon 12. *Molecular Carcinogenesis*. 2010; 3: 296-301.
- Tsutsumi M, Kondoh S, Noguchi O, Horiguchi K, Kobayashi E, Okita S, et al. K - ras Gene Mutation in Early Ductal Lesions Induced in a Rapid Production Model for Pancreatic Carcinomas in Syrian Hamsters. *Japanese Journal of Cancer Research*. 1993; 84.
- M M, JP B, EG H, RA W. Histogenesis of early preneoplastic lesions induced by N-nitrosobis(2-oxopropyl)amine in exocrine pancreas of hamsters. *International journal of pancreatology : official journal of the International Association of Pancreatology*. 1989; 4: 127-37.
- Pour PM. Experimental pancreatic cancer. *Am J Surg Pathol*. 1989; 13 Suppl 1: 96-103.
- Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell*. 2003; 4: 437-50.
- Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell*. 1990; 61: 759-67.
- Orban PC, Chui D, Marth JD. Tissue- and site-specific DNA recombination in transgenic mice. *Proc Natl Acad Sci U S A*. 1992; 89: 6861-5.
- Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc Natl Acad Sci U S A*. 1992; 89: 5547-51.
- Schonig K, Schwenk F, Rajewsky K, Bujard H. Stringent doxycycline dependent control of CRE recombinase in vivo. *Nucleic Acids Res*. 2002; 30: e134.
- French D, Smith A, Powers MP, Wu AH. KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. *Clin Chim Acta*. 2011; 412: 1578-81.
- Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. *Genes Dev*. 2003; 17: 3112-26.
- Hingorani SR, Wang L, Multani AS, Combs C, Deramandt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell*. 2005; 7: 469-83.
- Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. *Cancer Cell*. 2007; 11: 229-43.
- Kojima K, Vickers SM, Adsay NV, Jhala NC, Kim HG, Schoeb TR, et al. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia. *Cancer Res*. 2007; 67: 8121-30.
- Kim SK, MacDonald RJ. Signaling and transcriptional control of pancreatic organogenesis. *Curr Opin Genet Dev*. 2002; 12: 540-7.
- Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, Fujitani S, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. *Genes Dev*. 2006; 20: 3147-60.
- Schmied BM, Ulrich AB, Matsuzaki H, El-Metwally TH, Ding X, Fernandes ME, et al. Biologic instability of pancreatic cancer xenografts in the nude mouse. *Carcinogenesis*. 2000; 21: 1121-7.
- Garofalo A, Chirivi RG, Scanziani E, Mayo JG, Vecchi A, Giavazzi R. Comparative study on the metastatic behavior of human tumors in nude, beige/nude/xid and severe combined immunodeficient mice. *Invasion Metastasis*. 1993; 13: 82-91.
- Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. *Pancreas*. 2004; 29: 193-203.
- Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, et al. Phenotype and genotype of pancreatic cancer cell lines. *Pancreas*. 2010; 39: 425-35.
- Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. *Nature*. 2013; 500: 415-21.
- Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. *Nat Commun*. 2015; 6: 6744.
- Kern SE. Molecular genetic alterations in ductal pancreatic adenocarcinomas. *Med Clin North Am*. 2000; 84: 691-5, xi.
- Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. *Virchows Arch*. 2003; 442: 444-52.
- Monti P, Marchesi F, Reni M, Mercalli A, Sordi V, Zerbi A, et al. A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. *Virchows Arch*. 2004; 445: 236-47.
- Panayiotis L, Kengo K, Masaaki T, Tatsuhiro S, Michie S, Setsuo H. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. *Pancreas*. 2004; 29: 193.
- Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. *Virchows Arch*. 2001; 439: 798-802.
- Boyden S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. *J Exp Med*. 1962; 115: 453-66.
- Cai AQ, Landman KA, Hughes BD. Multi-scale modeling of a wound-healing cell migration assay. *J Theor Biol*. 2007; 245: 576-94.
- Stahle M, Veit C, Bachfischer U, Schierling K, Skripczynski B, Hall A, et al. Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. *J Cell Sci*. 2003; 116: 3835-46.
- Lin M, DiVito MM, Merajver SD, Boyanapalli M, van Golen KL. Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1. *Mol Cancer*. 2005; 4: 21.
- Fogar P, Greco E, Basso D, Habeler W, Navaglia F, Zamboni CF, et al. Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. *Eur J Surg Oncol*. 2003; 29: 721-30.
- Eibl G, Reber HA. A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer. *Pancreas*. 2005; 31: 258-62.
- Kim MP, Evans DB, Huamir W, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. *Nature Protocols*. 2009; 4: 1670-80.
- Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. *Nat Rev Cancer*. 2002; 2: 563-72.
- Campos-Campos F. [Cancer of the pancreas]. *Rev Gastroenterol Mex*. 1997; 62: 202-11.
- Mai R, Anzai Y. Ultrasmall superparamagnetic iron oxide enhanced MR imaging for lymph node metastases. *Radiography*. 2007; 13: e73-e84.
- Abdollahi A, Jangjoo A, Dabbagh Kakhki VR, Rasoul Zakavi S, Memar B, Naser Forghani M, et al. Factors affecting sentinel lymph node detection failure in breast cancer patients using intradermal injection of the tracer. *Rev Esp Med Nucl*. 2010; 29: 73-7.
- Xinzhe YU, Hengchao LI, Deliang FU, Jin C, Ji LI. Characterization of the role of the photosensitizer, deuterporfin, in the detection of lymphatic metastases in a pancreatic cancer xenograft model. *Oncology Letters*. 2015; 10: 1430.
- Koide N, Yamada T, Shibata R, Mori T, Fukuma M, Yamazaki K, et al. Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. *Clinical Cancer Research*. 2006; 12: 2419-26.
- Nomura H, Nishimori H, Yasoshima T, Hata F, Tanaka H, Nakajima F, et al. A new liver metastatic and peritoneal dissemination model established from the same human pancreatic cancer cell line: analysis using cDNA macroarray. *Clin Exp Metastasis*. 2002; 19: 391-9.
- Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. *Mol Cancer Ther*. 2011; 10: 1311-6.

56. Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, Zou GM, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. *Molecular Cancer Therapeutics*. 2009; 8: 310-4.
57. Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE, et al. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. *Ann Surg Oncol*. 2012; 19 Suppl 3: S395-403.
58. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. *Nat Med*. 2011; 17: 1514-20.
59. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. *Clin Cancer Res*. 2012; 18: 5314-28.
60. Smith GH. The Culture of Organs. *Yale Journal of Biology & Medicine*. 1938; 11: 162-.
61. Jones RT, Hudson EA, Ms JHR. A review of in vitro and in vivo culture techniques for the study of pancreatic carcinogenesis. *Cancer*. 1981; 47: 1490-6.
62. Marciniak A, Selck C, Friedrich B, Speier S. Mouse Pancreas Tissue Slice Culture Facilitates Long-Term Studies of Exocrine and Endocrine Cell Physiology in situ. *PLOS ONE*. 2013; 8: e78706.
63. van Geer MA, Kuhlmann KF, Bakker CT, ten Kate FJ, Oude Elferink RP, Bosma PJ. Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices. *World Journal of Gastroenterology*. 2009; 15: 1359-66.
64. Sempere LF, Gunn JR, Korc M. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGF $\beta$  in pancreatic cancer cells. *Cancer Biology & Therapy*. 2011; 12: 198-207.
65. Fanjul M, Hollande E. Morphogenesis of "Duct-like" Structures in Three-Dimensional Cultures of Human Cancerous Pancreatic Duct Cells (Capan-1). *In Vitro Cellular & Developmental Biology Animal*. 1993; 29A: 574-84.
66. Ricci C, Mota C, Moscato S, D'Alessandro D, Ugel S, Sartoris S, et al. Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. *Biomatter*. 2014; 4: e955386.
67. Boj Sylvia F, Hwang C-I, Baker Lindsey A, Chio Iok In C, Engle Dannielle D, Corbo V, et al. Organoid Models of Human and Mouse Ductal Pancreatic Cancer. *Cell*. 2015; 160: 324-38.
68. Walsh AJ, Castellanos JA, Nagathihalli NS, Merchant NB, Skala MC. Optical Imaging of Drug-Induced Metabolism Changes in Murine and Human Pancreatic Cancer Organoids Reveals Heterogeneous Drug Response. *Pancreas*. 2016; 45: 863-9.
69. Huang L, Holtzinger A, Jagan I, BeGora M, Lohse I, Ngai N, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. *Nature Medicine*. 2015; 21: 1364.
70. Li X, Nadauld L, Ootani A, Corney DC, Pai RK, Gevaert O, et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. *Nature Medicine*. 2014; 20: 769.
71. Nuciforo S, Fofana I, Matter MS, Blumer T, Calabrese D, Boldanova T, et al. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. *Cell Reports*. 2018; 24: 1363-76.
72. Tiriac H, Bucobo JC, Tzimas D, Grewel S, Lacombe JF, Rowehl LM, et al. Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy for personalized cancer treatment. *Gastrointestinal Endoscopy*. 2017; 85: AB50-AB1.
73. Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville T, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. *Cancer Discovery*. 2018: CD-18-0349.
74. Fleur W, Marc VDW, Marlous H, Dijkstra KK, Oscar K, Thomas K, et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. *Proceedings of the National Academy of Sciences of the United States of America*. 2015; 112: 13308-11.
75. Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. *Nature Medicine*. 2015; 21: 256.
76. Drost J, Jaarsveld RHV, Ponsioen B, Zimmerlin C, Bostel RV, Buijs A, et al. Sequential cancer mutations in cultured human intestinal stem cells. *Nature*. 2015; 521: 43-7.
77. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science*. 2008; 321: 1801-6.
78. Morris JPt, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. *Nat Rev Cancer*. 2010; 10: 683-95.
79. Li K, Yau FW, Fok TF, So KW, Li CK, Yuen PM. Haematopoietic stem and progenitor cells in human term and preterm neonatal blood. *Vox Sanguinis*. 2010; 80: 162-9.
80. Chen WH, Horoszewicz JS, Leong SS, Shimano T, Penetrante R, Sanders WH, et al. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. *In Vitro*. 1982; 18: 24-34.
81. Kim YW, Kern HF, Mullins TD, Koriwchak MJ, Metzgar RS. Characterization of clones of a human pancreatic adenocarcinoma cell line representing different stages of differentiation. *Pancreas*. 1989; 4: 353-62.
82. Gower WR, Jr., Risch RM, Godellas CV, Fabri PJ. HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. *In Vitro Cell Dev Biol Anim*. 1994; 30A: 151-61.
83. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. *Int J Cancer*. 1977; 19: 128-35.
84. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. *Int J Cancer*. 1975; 15: 741-7.
85. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, et al. Characterization of a new primary human pancreatic tumor line. *Cancer Invest*. 1986; 4: 15-23.
86. Dahiya R, Kwak KS, Byrd JC, Ho S, Yoon WH, Kim YS. Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-1 mucin gene. *Cancer Res*. 1993; 53: 1437-43.
87. Fanjul M, Hollande E. Morphogenesis of "duct-like" structures in three-dimensional cultures of human cancerous pancreatic duct cells (Capan-1). *In Vitro Cell Dev Biol Anim*. 1993; 29A: 574-84.
88. Kyriazis AP, Kyriazis AA, Scarpelli DG, Fogh J, Rao MS, Lepera R. Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. *Am J Pathol*. 1982; 106: 250-60.
89. LeDonne DM. Trends in morbidity and use of health services by women veterans of Vietnam. *Navy Med*. 1988; 79: 22-5.
90. Schoumacker RA, Ram J, Iannuzzi MC, Bradbury NA, Wallace RW, Hon CT, et al. A cystic fibrosis pancreatic adenocarcinoma cell line. *Proc Natl Acad Sci U S A*. 1990; 87: 4012-6.
91. Iwamura T, Katsuki T, Ide K. Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. *Jpn J Cancer Res*. 1987; 78: 54-62.
92. Iwamura T, Taniguchi S, Kitamura N, Yamanari H, Kojima A, Hidaka K, et al. Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2). *J Gastroenterol Hepatol*. 1992; 7: 512-9.
93. Kyriazis AP, McCombs WB, 3rd, Sandberg AA, Kyriazis AA, Sloane NH, Lepera R. Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse. *Cancer Res*. 1983; 43: 4393-401.
94. Owens RB, Smith HS, Nelson-Rees WA, Springer EL. Epithelial cell cultures from normal and cancerous human tissues. *J Natl Cancer Inst*. 1976; 56: 843-9.
95. Morgan RT, Woods LK, Moore GE, Quinn LA, McGavran L, Gordon SG. Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma. *Int J Cancer*. 1980; 25: 591-8.
96. Okabe T, Yamaguchi N, Ohsawa N. Establishment and characterization of a carcinoembryonic antigen (CEA)-producing cell line from a human carcinoma of the exocrine pancreas. *Cancer*. 1983; 51: 662-8.
97. Egami H, Takiyama Y, Cano M, Houser WH, Pour PM. Establishment of hamster pancreatic ductal carcinoma cell line (PC-1) producing blood group-related antigens. *Carcinogenesis*. 1989; 10: 861-9.
98. Erill N, Cuatrecasas M, Sancho FJ, Farre A, Pour PM, Lluís F, et al. K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines. *Am J Pathol*. 1996; 149: 1333-9.
99. Chang BK, Gutman R. Chemotherapy of pancreatic adenocarcinoma: initial report on two transplantable models in the Syrian hamster. *Cancer Res*. 1982; 42: 2666-70.
100. Morita Y, Moriai T, Takiyama Y, Makino I. Establishment and characterization of a new hamster pancreatic cancer cell line: the biological activity and the binding characteristics of EGF or TGF- $\alpha$ . *Int J Pancreatol*. 1998; 23: 41-50.
101. Batra SK, Metzgar RS, Worlock AJ, Hollingsworth MA. Expression of the human MUC1 mucin cDNA in a hamster pancreatic tumor cell line HP-1. *Int J Pancreatol*. 1992; 12: 271-83.
102. Saito S, Nishimura N, Kubota Y, Yamazaki K, Shibuya T, Sasaki H. Establishment and characterization of a cultured cell line derived from nitrosamine-induced pancreatic ductal adenocarcinoma in Syrian golden hamsters. *Gastroenterol Jpn*. 1988; 23: 183-94.
103. Townsend CM, Jr., Franklin RB, Gelder FB, Glass E, Thompson JC. Development of a transplantable model of pancreatic duct adenocarcinoma. *Surgery*. 1982; 92: 72-8.
104. Sumi S, Beauchamp RD, Townsend CM, Jr., Pour PM, Ishizuka J, Thompson JC. Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. *Pancreas*. 1994; 9: 657-61.
105. Bardi G, Parada LA, Bomme L, Pandis N, Johansson B, Willen R, et al. Cytogenetic findings in metastases from colorectal cancer. *Int J Cancer*. 1997; 72: 604-7.
106. Wang Y, Zhang Y, Yang J, Ni X, Liu S, Li Z, et al. Genomic sequencing of key genes in mouse pancreatic cancer cells. *Curr Mol Med*. 2012; 12: 331-41.
107. Zechner D, Burtin F, Amme J, Lindner T, Radecke T, Hadlich S, et al. Characterization of novel carcinoma cell lines for the analysis of therapeutic strategies fighting pancreatic cancer. *Cell Biosci*. 2015; 5: 51.
108. Partecke IL, Kaeding A, Sandler M, Albers N, Kühn JP, Speerforck S, et al. In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model. *Bmc Cancer*. 2011; 11: 40.
109. Partecke LI, Sandler M, Kaeding A, Weiss FU, Mayerle J, Dummer A, et al. A Syngeneic Orthotopic Murine Model of Pancreatic Adenocarcinoma in the

- C57/BL6 Mouse Using the Panc02 and 6606PDA Cell Lines. *European Surgical Research*. 2011; 47: 98-107.
110. Longnecker DS, Lilja HS, French J, Kuhlmann E, Noll W. Transplantation of azaserine-induced carcinomas of pancreas in rats. *Cancer Lett*. 1979; 7: 197-202.
111. Christophe J. Pancreatic tumoral cell line AR42J: an amphicrine model. *Am J Physiol*. 1994; 266: G963-71.